AMVUTTRA®
As listed in the register: AMVUTTRA®, Injektionslösung in einer Fertigspritze
·
- Prescription only
- Pain, sleep, mood, epilepsy and the brain
- Active substance
- Vutrisiranum natricum
- Made by
- Alnylam Switzerland GmbH
- Source
- Official label
Quoted from the official source. Not yet reviewed by Mediclarum — the leaflet in your pack is authoritative.
What it is for
- Amvuttra wird zur Behandlung der hereditären Transthyretin-Amyloidose bei erwachsenen Patienten mit Polyneuropathie der Stadien 1 oder 2 (hATTR-PN) angewendet Amvuttra wird zur Behandlung der Wildtyp- oder hereditären Transthyretin-Amyloidose bei erwachsenen Patienten mit Kardiomyopathie (ATTR-CM) angewendet.
From the official label · 2026-09-30 · Swissmedic
Same active substance, strength and form in other countries
Matched on active substance, strength and kind of form only. This is not a statement that the products are equivalent or interchangeable: other ingredients, release and approved uses can differ — ask a pharmacist before swapping.
Medicine passport: one printable page to show a pharmacist abroad
European UnionNo exact match for this strength and form
SpainNo exact match for this strength and form
CanadaNo exact match for this strength and form
NetherlandsNo exact match for this strength and form
Details
| Made by | Alnylam Switzerland GmbH |
|---|---|
| Active substance | Vutrisiranum natricum |
| Used in | Pain, sleep, mood, epilepsy and the brain |
| Classification | N07XX18 · Pain, sleep, mood, epilepsy and the brain |
| Dispensing (as stated by the register) | Abgabekategorie B |
| Name in the register | AMVUTTRA®, Injektionslösung in einer Fertigspritze |
| Packs | 1 Fertigspritze(n) |
| Zulassungsnummer | 69074 |
| Dosisstärke | 1 |
Source: Zugelassene Packungen Humanarzneimittel · 2026-09-30 · not reviewed by a clinician
Quelle: Swissmedic. The publisher’s terms do not grant reproduction, so text is shortened and linked. Publisher’s terms.